Catalent (NYSE:CTLT) will collaborate with Johnson & Johnson (NYSE:JNJ)
unit Janssen Pharmaceutical Companies to accelerate manufacturing
capacity and prepare for large-scale production of J&J’s lead
COVID-19 vaccine candidate.
The parties will jointly invest in the scale-up of
capacity over the coming months. Catalent expects to hire ~300
additional employees at its Bloomington, IN site starting in July with
the objective of operational readiness for 24/7 production by January
2021.
Financial terms are not disclosed.
CTLT is up 6% premarket while JNJ is up a fraction, both on light volume.
https://seekingalpha.com/news/3565990-j-and-j-teams-up-catalent-to-supply-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.